EPC-TM-NET
Targeting the tumour microenvironment to improve pancreatic cancer prognosis
| Coordinatore | PHILIPPS UNIVERSITAET MARBURG
Organization address
address: Biegenstrasse 10 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Sito del progetto | http://epcnet.eu/ |
| Totale costo | 4˙230˙298 € |
| EC contributo | 3˙000˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2010-two-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-02-01 - 2014-07-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
PHILIPPS UNIVERSITAET MARBURG
Organization address
address: Biegenstrasse 10 contact info |
DE (MARBURG) | coordinator | 626˙777.00 |
| 2 |
FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III
Organization address
address: CALLE MELCHOR FERNANDEZ ALMAGRO 3 contact info |
ES (MADRID) | participant | 550˙000.00 |
| 3 |
Nome Ente NON disponibile
Organization address
address: Domstrasse 11 contact info |
DE (GREIFSWALD) | participant | 270˙000.00 |
| 4 |
THE UNIVERSITY OF LIVERPOOL
Organization address
address: Brownlow Hill, Foundation Building 765 contact info |
UK (LIVERPOOL) | participant | 248˙800.00 |
| 5 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | participant | 207˙560.00 |
| 6 | Concentris Research Management GmbH | DE | participant | 202˙838.00 |
| 7 |
UNIVERSITA DEGLI STUDI DI VERONA
Organization address
address: VIA DELL ARTIGLIERE 8 contact info |
IT (VERONA) | participant | 145˙000.00 |
| 8 |
CANCER RESEARCH UK
Organization address
address: ST JOHN STREET 407 ANGEL BUILDING contact info |
UK (LONDON) | participant | 144˙365.00 |
| 9 |
TECHNISCHE UNIVERSITAET MUENCHEN
Organization address
address: Arcisstrasse 21 contact info |
DE (MUENCHEN) | participant | 138˙600.00 |
| 10 |
KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN
Organization address
address: ISMANINGER STRASSE 22 contact info |
DE (MUENCHEN) | participant | 131˙400.00 |
| 11 |
Bayer Pharma AG
Organization address
address: Muellerstrasse 178 contact info |
DE (Berlin) | participant | 76˙462.00 |
| 12 |
Axcentua Pharmaceuticals AB
Organization address
address: Alfred Nobels Alle 10 contact info |
SE (Huddinge) | participant | 72˙440.00 |
| 13 |
FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR
Organization address
address: Via Olgettina 60 contact info |
IT (MILANO) | participant | 60˙000.00 |
| 14 |
UNIVERSITA DEGLI STUDI DI TORINO
Organization address
address: Via Giuseppe Verdi 8 contact info |
IT (TORINO) | participant | 60˙000.00 |
| 15 |
NATIMAB THERAPEUTICS SRL
Organization address
address: VIA RIBES 5 contact info |
IT (COLLERETTO GIACOSA TORINO) | participant | 45˙000.00 |
| 16 |
LAB 21 LIMITED
Organization address
address: Cambridge Science Park 184 contact info |
UK (Cambridge) | participant | 20˙758.00 |
| 17 |
Fondazione Centro San Raffaele
Organization address
address: Via Olgettina 60 contact info |
IT (Milano) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Pancreatic cancer is one of the most lethal human cancers with a five-year survival rate of less than 5%. Late presentation and a high level of resistance to chemotherapeutic drugs are among the major reasons for this dismal prognosis. The presence of the highest degree of desmoplasia among all solid tumours and the fact that chronic inflammatory pancreatic disease is associated with an increased risk for pancreatic cancer indicate, that the tumour microenvironment is of particular importance for carcinogenesis in the pancreas. The long-term objective of this proposal is to increase survival of pancreatic cancer patients by exploring the contribution of the tumour microenvironment to the failure of presently available oncological treatments. For this purpose the clinical observation will be reverse-translated into innovative in-vitro and mouse models closely mimicking the human disease. This will allow a profound study of the mechanistic basis of treatment failure by deciphering the complex network between components of the microenvironment and cancer cells leading to increased resistance to chemotherapy and infiltrative growth along adjacent lymphatic and neural structures as well as metastatic spread. Identification of cancer (stem) cell-autonomous as well as stromal-derived mediators of invasion and chemoresistance will lead to novel drug targets to overcome the current therapeutic dilemma. The consortium has been specifically designed to include all required levels of expertise: 1) surgical and medical oncology groups conducting the largest clinical trials for pancreatic cancer in Europe, 2) expert pancreatic pathologists, 3) basic scientists focused on the study of carcinogenesis and tumour microenvironment interactions in the pancreas, 4) molecular oncology groups that have developed genetically engineered mouse models faithfully recapitulating human pancreatic cancer, as well as 5) pharmaceutical industry specialised on drug development.'
Introduzione (Teaser)
The role of the microenvironment in tumour progression is prompting scientists to develop innovative therapeutic solutions that target the tumour stroma. This approach is expected to abolish the growth advantage of tumour cells and facilitate the accessibility of chemotherapeutic agents.
Altri progetti dello stesso programma (FP7-HEALTH)
HISCREENDIAG (2009)
Building a Tool to Evaluate and Improve Health Investments in Screening and Diagnosis of disease
Read MoreOTC SOCIOMED (2009)
ASSESSING THE OVER-THE-COUNTER MEDICATIONS IN PRIMARY CARE AND TRANSLATING THE THEORY OF PLANNED BEHAVIOUR INTO INTERVENTIONS
Read MoreSTRONG (2012)
European Consortium for the Study of a Topical Treatment of Neovascular Glaucoma
Read More